# Curriculum Vitae-Donna D. Zhang, Ph.D.

Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ Phone: (520) 626-9918; Fax: (520) 626-2466; Email: <u>dzhang@pharmacy.arizona.edu</u>

#### EDUCATION:

- 1997 Ph.D. in Molecular Toxicology, New York University, Nelson Institute of Environmental Medicine, New York, New York. *"Molecular Cloning and Characterization of a novel gene, Cap43, that is specifically induced by Ni2+ compounds."* Advisor: Dr. Max Costa
- 1993 M.S. in Molecular Toxicology, New York University, Nelson Institute of Environmental Medicine, New York, New York. *"Effect of second-hand smoke in atherosclerosis."* Advisor: Dr. Arthur Penn

#### **EMPLOYMENT:**

2019-present Associate Director of Superfund Research Program.

- 2019-present Musil Family Endowed Chair in Drug Discovery.
- 2013-present Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ
- 2011-2013 Associate Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ.
- 2005-2011 Assistant Professor, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ.
- 1999-2005 Research Assistant Professor, University of Missouri-Columbia, Department of Biochemistry, Columbia, MO.
- 1997-1999 Post-doctoral Fellow (with Dr. David B. Warheit), DuPont-Haskell Laboratory, Inhalation Toxicology, Newark, DE.

### HONORS AND AWARDS:

- 2019 Dr. James R. Halpert Faculty Research Award
- 2013 Centennial Top 100 Alumni Achievement Hall of Fame of Ningbo 5<sup>th</sup> high School (0.1%)
- 2012 The Society of Toxicology Achievement Award
- 2006 NIH/NIEHS Outstanding New Environmental Health Scientist Award
- 1999 DuPont Young Investigator Award

### PATENTS:

<u>Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers</u> DD Zhang, GT Wondrak US Patent App. 16/060,742, 2018

Activators of nrf2-dependent photoprotection and related uses thereof GT Wondrak, DD Zhang US Patent App. 15/753,514, 2018 Compositions and methods for treating and preventing lung injury DD Zhang, GT Wondrak, JGN Garcia, T Wang US Patent App. 15/765,777, 2018

### **SERVICE/OUTREACH:**

#### Intramural 2019-The University P&T Committee 2016-2017 **Research Affairs Committee UAHS Space Committee** 2016 2016-College Space Committee 2015-T32 Training grant executive committee Departmental P&T Committee 2014-2009-College of Pharmacy Research Affairs Committee 2009-Member, Bio5 Institute Member, Cancer Biology Graduate Program 2006-2006-Member, Biological Chemistry Graduate Program Member, Biomedical Engineering Graduate Interdisciplinary Program 2006-2006-Member, Southwest Environmental Health Sciences Center 2006-Member, Cancer Prevention and Control Program, Arizona Cancer Center Mentor, Keep Engaging Youth in Science (KEYS) research program for K-12 students and 2006high school teachers Member, College of Pharmacy Computer Committee 2006-2008 Extramural NIH, Special Emphasis Panel review for SPORE grant, Oncology Translational Clinical IRG 2019 President of Mechanisms Specialty Section of the Society of Toxicology 2018 NIH, Systemic injury by Environmental Exposure (SIEE)-member 2018-2022 National Research Foundation of Korea, reviewer 2018 2018 NIH, Bioengineering Sciences and Technologies (BST), IRG NIH, Systemic injury by Environmental Exposure (SIEE) 2017 NIH, Special Emphasis Panel review for SPORE grant, Oncology Translational Clinical IRG 2017 2017 NIH, Special Emphasis Panel review, AREA R15 Medical Research Council, reviewer 2017 2017 Editor, "Nrf2-Keap1" forum, Antioxidants & Redox Signaling 2016 NIH, Special Emphasis Panel Members (SEP), reviewer NIH, Special Emphasis Panel review, AREA R15 2016 2016 NIH, NIEHS Outstanding New Environmental Scientist (ONES) Award 2016 Vice-president of Mechanisms Specialty Section of the Society of Toxicology 2016-2019 Associate Editor, Molecular Carcinogenesis 2015 Medical Research Council, reviewer 2015 NIH, NIEHS Career Award (K99) External evaluator, faculty P&T process, College of Medicine, Dentistry and Nursing, 2015 University of Dundee, Dundee 2015 External evaluator, faculty P&T process, Department of Medicinal Chemistry & Molecular Pharmacology, College of Pharmacy, Purdue University 2015 External evaluator, faculty P&T process, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago External evaluator, faculty P&T process, Department of Cell Biology and Physiology in the 2015 School of Medicine at UNC-Chapel Hill 2014 NIH, the stage 2 Distinguished Editorial panel for Botanical Dietary Supplement Research Centers (BDSRC) (P50)

2014	NIH, the stage 2 Distinguished Editorial panel for Centers for Advancing Natural Products Innovation and Technology Centers (CANPIT) (U41)
2014	NIH NIEHS Outstanding New Environmental Scientist (ONES) Award
2014	Cancer Research UK Expert Programme Review Panel
2012-2016	National Institutes of Health review committee, Chemo/Dietary Prevention Study Section (CDP/NIH)-member
2013	NIH, reviewer for the National Center for Complementary and Alternative Medicine (NCCAM/NIH)
2013-	External Advisory Board Member for NIAID P01 Signaling in airway inflammation, UTMB Galveston, PI: Allan Brasier
2013-	Research Funding Committee, Society of Toxicology
2012	Woman in Toxicology, Society of Toxicology
2012	External reviewer, Center in Molecular Toxicology, Vanderbilt University School of Medicine, pilot grant
2012	The Leukemia & Lymphoma Society, Medical Research Council
2011	Reviewer, King Abdulaziz City for Science and Technology, Saudi Arabia
2011	Reviewer, Association for International Cancer Research in the United Kingdom (AICR)
2011	External reviewer, faculty promotion process, Department of Pharmaceutical Sciences, University of Colorado
2011	Organizer and Chair, "New insights into the Nrf2-Keap1 pathway and its impact on human disease" symposium, Society of Toxicology annual meeting
2010-2011	President, Mountain West Regional Chapter, the Society of Toxicology
2010	Reviewer, National Science Foundation, Molecular and Cellular Biosciences Division
2010	Chair Oxidative Injury and Redox Biology poster session. Society of Toxicology annual
2010	meeting
2010	Organizing committee and chair of "Cellular & Molecular Responses to BRIs," Biological Reactive Intermediates International Conference VIII, Barcelona, Spain
2010	Editor, "Nrf2-Keap1" forum, Antioxidants & Redox Signaling
2009-2013	Editorial board member, Toxicology and Applied Pharmacology
2009	Reviewer, Wellcome Trust, United Kingdom
2009	NIH, National Institute of Environmental Health Sciences, special emphasis panel study section to review P01 and P20 children center grants
2009-2012	NIH, National Institutes of Health review committee, Chemo/Dietary Prevention Study Section
2009-2010	Vice-President, Mountain West Regional Chapter, Society of Toxicology
2009-2010	Organizer, Mountain West Regional Chapter, Society of Toxicology annual meeting
2009	Chair, Reactive Oxygen Species Stimulated Signaling poster session, Society of Toxicology
2009	Annual meeting Deviewer, Concer Dessereb, United Kingdom Science Funding Committee
2000	Reviewer, Cancer Research, Onlieu Kingdom Science Funding Committee
2008	Pharmaceutical Sciences' sub-area
2008	Chair, Oxidative Signaling and Redox Biology symposium, Society of Toxicology annual meeting
2007-2011	Member, Career Resource and Development Committee, Society of Toxicology
2006	Reviewer, Italian National Centre for Rare Disease at the Instituto Superiore di Sanità, Italian Public Health Institute of Rome

# TEACHING: Courses

Cell communications and signal transduction (PCOL 630B)

- Course Coordinator
- Required course for Ph.D. and M.S. degrees in Pharmacology and Toxicology

• 15 lectures each fall semester

Seminar (PCOL 696A and 696B)

- Course Coordinator
- Required course for Ph.D. and M.S. degrees in Pharmacology and Toxicology

Science of Pharmacology (PCOL 871A)

- Required course for Pharm. D., Ph.D. and M.S. degree
- 2 lectures each fall semester

Science of Pharmacology (PCOL 871B)

- Required course for Pharm. D., Ph.D. and M.S. degree
- 4 lectures each spring semester

General and Systems Toxicology (PCOL602A)

- Required course for Ph.D. and M.S. degree
- 6 lectures each fall semester

Advanced Toxicology (PCOL 596C)

- Required course for Ph.D. and M.S. degrees in Pharmacology and Toxicology
- 1 lecture each fall and spring semester

Individualized Medicine: Applied Pharmacogenetics (PHPR 887)

- Required course for Ph.D. and M.S. degree in Pharmacology and Toxicology and Pharm. D. students
- 3 lectures each spring semester

Case Study in Biochemical Pharmacology (PCOL 870/871)

- Authored "Holly Beach" case
- Required course for Pharm.D. students
- 3 case studies each fall and spring semester

# Ph.D. Graduate Committees

Major advisor:

- Aryatara Shakya, Arizona Biological and Biomedical Sciences (ABBS), majoring in Pharmacology and Toxicology, 2019- (thesis advisor)
- Cody Schmidlin, Arizona Biological and Biomedical Sciences (ABBS), majoring in Cancer Biology, 2016- (thesis advisor)
- Elisa Montserrat Rojo de la Vega Guinea, Arizona Biological and Biomedical Sciences (ABBS), majoring in Cancer Biology, 2013-2018 (thesis advisor)
- Bryan Harder, Pharmacology and Toxicology, 2013-2017 (thesis advisor)
- Tongde Wu, Pharmacology and Toxicology, 2009- 2013 (thesis advisor)
- Alexandra G. Lau, Pharmacology and Toxicology, 2007-2012 (thesis advisor)
- Nicole F. Villeneuve, Pharmacology and Toxicology, 2006-2011 (thesis advisor)
- Zheng Sun, Pharmacology and Toxicology, 2005-2009 (thesis advisor)
- Huihui Wang, Chinese Medical University, China, 2010 (co-thesis advisor)
- Yi Zheng, Chinese Medical University, China, 2010-2012 (co-thesis advisor)
- Yu Du, Pharmaceutical Sciences, Shandong University, China, 2007-2008 (cothesis advisor)

Ph.D. committee member:

- Argel Islas Robles, Pharmacology and Toxicology 2014-
- Hui Li, Pharmacology and Toxicology 2013-2017
- Shue Wang, Aerospace & Mechanical Engineering Department 2011-2016
- Joseph Tillotson, Pharmacology and Toxicology 2013-2016
- Aram B Cholanians, Pharmacology and Toxicology, 2011-2016
- Anika Dzierlenga, Pharmacology and Toxicology, 2010-2016
- Ryan Canatsey, Pharmacology and Toxicology, 2010-2016
- Jessica Sapiro, Pharmacology and Toxicology, 2010-2016
- Nick Mastrandrea, Pharmacology and Toxicology, 2008-2014
- Kevin Bray, Cell and Developmental Biology, Rutgers University, -2011 (advisor: Dr. Eileen White)
- Fei Zhao, Pharmacology and Toxicology, 2009-2013
- April D. Lake, Pharmacology and Toxicology, 2008-2013
- Parvathi Sinha, Pharmacology and Toxicology, 2008-2010
- Matthew Keane Medeiros, Pharmacology and Toxicology, 2007-2013
- Keika Okamoto, Pharmacology and Toxicology, 2008-2009
- Rhiannon N. Hardwick, Pharmacology and Toxicology, 2007-2012
- Ana Tula Sanchez, Pharmacology and Toxicology, 2006-2013
- Evisabel Arauz Craig, Pharmacology and Toxicology, 2006-2011
- Alicia Marie Bolt, Pharmacology and Toxicology, 2006-2012
- Shawn Michael Wnek, Pharmacology and Toxicology, 2006-2011
- Aaron Goldman, Cancer Biology, 2005-2010
- Ingrid Leal Druwe, Pharmacology and Toxicology, 2005-2012
- Matthew David Merrell, Pharmacology and Toxicology, 2006-2011
- Terence Henry Sy, Pharmacology and Toxicology, 2007-2009
- Christopher M Cabello, IGERT committee, 2007-2012

### MEDIA:

- The Daily Widlcat "Six scientific successes that stole the show this year": <u>http://www.wildcat.arizona.edu/article/2016/10/in-case-you-missed-them-six-scientific-successes-that-stole-the-show-this-year</u>
- Science News: <u>http://www.sciencemag.org/news/2016/04/some-diabetes-drugs-may-help-cancer-spread-mice</u>
- FOCUS newsletter: http://www.allergyresearchgroup.com/focus/201505.htm
- Medical News Today: <u>http://www.medicalnewstoday.com/releases/295410.php</u>
- <u>Health News Digest</u>, <u>Futurity (link is external)</u>
- KVOA (link is external)
- UA News (link is external)
- UA Now (link is external)
- MDLinx (link is external)
- EurekAlert! (link is external)
- MedicalXpress (link is external).
- NBC local news; KVOA Chanel 4; segment Kristi's Kids <u>http://www.kvoa.com/news/kristi-s-kids-learns-about-new-super-fruit/</u>

# **PUBLICATIONS:**

(Based on Google Scholar as of July 23, 2020: total citations 26654, h-index 63) Peer-Reviewed Publications:

- 122: Schmidlin CJ, Zeng T, Liu P, Wei Y, Dodson M, Chapman E, <u>Zhang DD</u>. Chronic arsenic exposure enhances metastatic potential via NRF2-mediated upregulation of SOX9. *Toxicol Appl Pharmacol*. 2020. PMID:32682831
- 121: Liu P, Dodson M, Dang D, Chapman E, <u>Zhang DD</u>. NRF2 negatively regulates primary ciliogenesis and hedgehog signalng. *PLoS Biol.* 2020. PMID:32053600
- 120: Rodrigues SD, Santos SS, Meireles T, Romero N, Glorieux G, Pecoits-Filho R, Zhang DD, Nakao LS. Uremic toxins promote accumulation of oxidized protein and increased sensitivity to hydrogen peroxide in endothelial cells by impairing the autophagic flux. *Biochem Biophys Res Commun.* 2019. PMID:31837804.
- 119: Liu P, Kerins MJ, Tian W, Neupana D, <u>Zhang DD</u>\*, Ooi A\*. Differential and overlapping targets of the transcriptional regulators NRF1, NRF2, and NRF3 in human cells. *J Biol Chem*. 2019. PMID:31628195.
- 118: Liu P, Tian W, Tao S, Tillotson J, Wijeratne EMK, Gunatilaka AAL, <u>Zhang DD</u>\*, Chapman E\*. Non-covalent NRF2 Activation Confers Greater Cellular Protection than Covalent Activation. *Cell Chem Biol*. 2019. PMID:31402317
- 117: Shi T, Wijeratne EMK, Solano C, Ambrose AJ, Ross AB, Norwood C, Orido CK, Grigoryan T, Tillotson J, Kang M, Luo G, Keegan BM, Hu W, Blagg BSJ, <u>Zhang DD</u>, Gunatilaka AAL, Chapman E. An Isoform-Selective PTP1B Inhibitor Derived from Nitrogen-Atom Augmentation of Radicicol. *Biochemistry*. 2019. PMID:31298844
- 116: Kerins MJ, Liu P, Tian W, Mannheim W, <u>Zhang DD\*</u>, Ooi A\*. Genome wide CRISPR screen reveals autophagy disruption as the convergence mechanism that regulates the NRF2 transcription factor. *Mol Cell Biol.* 2019. PMID: 31010806
- 115: Liu P, de la Vega MR, Dodson M, Yue F, Shi B, Fang D, Chapman E, Liu L, <u>Zhang DD</u>. Spermidine confers liver protection by enhancing NRF2 signaling through a MAP1S-mediated non-canonical mechanism. *Hepatology*. 2019. PMID:30873635
- 114: Shi T, Kaneko L, Sandino M, Busse R, Zhang M, Mason D, Machulis J, Ambrose AJ, <u>Zhang DD</u>, Chapman E. One-step synthesis of thieno[2,3-*d*]pyrimidin-4(3*H*)-ones via a catalytic fourcomponent reaction of ketones, ethyl cyanoacetate, S8 and formamide. *ACS Sustain Chem. Eng.* 2019. 7, 1524-1528.
- 113: Ambrose AJ, Zerio C, Schmidlin C, Sivinski J, Shi T, Ross AB, Widrick KJ, Johnson SM, <u>Zhang</u> <u>DD</u>, Chapman E. A high throughput substrate binding assay reveals hexachlorophene as an inhibitor of the ER-resident HSP70 chaperone GRP78. **Bioorg. Med. Chem. Lett.** 2019. PMID:31129054.
- 112: Shi T, Zerio CJ, Sivinski J, Ambrose AJ, Moore KT, Buckley T, Kaneko L, Zhang M, <u>Zhang DD</u>, and Chapman E. A one-step, atom economical synthesis of thieno[2,3-*d*]pyrimidin-4-amine derivatives via a four-component reaction. *Eur. J. Org. Chem*. 2019. PMID:31857792.
- 111: Xiao Y, Riahi R, Torab P, <u>Zhang DD</u>, Wong PK. Collective Cell Migration in 3D Epithelial Wound Healing. **ACS Nano**. 2019. PMID:30758172.
- 110: Liu P, Rojo de la Vega M, Sammani S, Mascarenhas JB, Kerins M, Dodson M, Sun X, Wang T, Ooi A, Garcia JGN, <u>Zhang DD</u>. RPA1 binding to NRF2 switches ARE-dependent transcriptional activation to ARE-NRE-dependent repression. **Proc Natl Acad Sci U S A**. 2018. PMID:30309964
- 109: Yang Y, Kong S, Zhang Y, Melo-Cardenas J, Gao B, Zhang Y, <u>Zhang DD</u>, Zhang B, Song J, Thorp E, Zhang K, Zhang J, Fang D. The endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 controls a critical checkpoint in B cell development in mice. *J Biol Chem*. 2018. PMID:29907570
- 108: Wei J, Yuan Y, Xu Y, Chen L, Zhang Y, Wang Y, Yang Y, Peek CB, Diebold L, Yang Y, Gao B, Jin C, Melo-Cardenas J, Chandel NS, <u>Zhang DD</u>, Pan H, Zhang K, Wang J, He F, Fang D. ERassociated ubiquitin ligase HRD1 programs liver metabolism by targeting multiple metabolic enzymes. *Nat Commun*. 2018. PMID:30201971
- 107: Ray S, Corenblum MJ, Anandhan A, Reed A, Ortiz FO, <u>Zhang DD</u>, Barnes CA, and Madhavan L. 2018. A role for Nrf2 expression in defining the aging of hippocampal neural stem cells. *Cell transplantation*. *Cell Transplant*. 2018. PMID:29871525
- 106: Rojo de la Vega M, <u>Zhang DD\*</u>, Wondrak GT\*. Topical Bixin Confers NRF2-Dependent Protection Against Photodamage and Hair Graying in Mouse Skin. *Front Pharmacol*. 2018. PMID:2963669

- 105: Dodson M, Liu P, Jiang T, Ambrose AJ, Luo G, Rojo de la Vega M, Cholanians AB, Wong PK, Chapman E, <u>Zhang DD</u>. Increased O-GlcNAcylation of SNAP29 drives arsenic-induced autophagic dysfunction. *Mol Cell Biol.* 2018. PMID:29507186
- 104: Dodson M, de la Vega MR, Harder B, Castro-Portuguez R, Rodrigues SD, Wong PK, Chapman E, <u>Zhang DD</u>. Low-level arsenic causes proteotoxic stress and not oxidative stress. **Toxicol Appl Pharmacol**. 2018. PMID:29408041
- 103: Wang S, Xiao Y, <u>Zhang DD</u>, Wong PK. Non-Canonical activation of NRF2: A gapmer aptamer nanobiosensor for real-time monitoring of transcription and translation in single cells. *Biomaterials.* 2018. PMID:29190498.
- 102: Tian W, Rojo de la Vega M, Schmidlin CJ, Ooi A, Zhang DD. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2). *J Biol Chem*. 2018. PMID:29255090.
- 101: Wang S, Sun J, Xiao Y, Lu Y, <u>Zhang DD</u>, Wong PK. Intercellular Tension Negatively Regulates Angiogenic Sprouting of Endothelial Tip Cells via Notch1-Dll4 Signaling. *Advanced Biosystems*. 2017. PMID:30662935.
- 100: Tao S, de la Vega MR, Chapman E, Ooi A, <u>Zhang DD</u>. The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. *Mol Carcinog.* 2018. PMID:28976703.
- 99: Tillotson J, Kedzior M, Guimarães L, Ross AB, Peters TL, Ambrose AJ, Schmidlin CJ, <u>Zhang DD</u>, Costa-Lotufo LV, Rodríguez AD, Schatz JH, Chapman E. ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A. *Bioorg Med Chem Lett.* 2017. PMID:28757063.
- 98: Tillotson J, Zerio CJ, Harder B, Ambrose AJ, Jung KS, Kang M, <u>Zhang DD\*</u>, Chapman E\*. Arsenic Compromises Both p97 and Proteasome Functions. *Chem Res Toxicol.* 2017. PMID:28636814.
- 97: Bao L, Wu J, Dodson M, Rojo de la Vega EM, Ning Y, Zhang Z, Yao M, <u>Zhang DD</u>, Xu C, Yi X. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. *Mol Carcinog.* 2017. PMID:28112439.
- 96: Gao B, Kong Q, Zhang Y, Yun C, Dent SYR, Song J, <u>Zhang DD</u>, Wang Y, Li X, Fang D. The Histone Acetyltransferase Gcn5 Positively Regulates T Cell Activation. *J Immunol.* 2017. PMID:28424240.
- 95: Harder B, Tian W, La Clair JJ, Tan AC, Ooi A, Chapman E, <u>Zhang DD</u>. Brusatol overcomes chemoresistance through inhibition of protein translation. *Mol Carcinog.* 2017. PMID:28019675
- 94: Tao S, Liu P, Luo G, Rojo de la Vega M, Chen H, Wu T, Tillotson J, Chapman E, <u>Zhang DD</u>. p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex. *Mol Cell Biol.* 2017. PMID:28115426.
- 93: Wang S, Sun J, <u>Zhang DD</u>, Wong PK. A nanobiosensor for dynamic single cell analysis during microvascular self-organization. *Nanoscale.* 2016. PMID:27547924
- 92: Kong S, Yang Y, Xu Y, Wang Y, Zhang Y, Melo-Cardenas J, Xu X, Gao B, Thorp EB, <u>Zhang DD</u>, Zhang B, Song J, Zhang K, Zhang J, Zhang J, Li H, Fang D. Endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 controls B-cell immunity through degradation of the death receptor CD95/Fas. **Proc Natl Acad Sci U S A.** 2016. PMID:27573825
- 91: Xu Y, Zhao F, Qiu Q, Chen K, Wei J, Kong Q, Gao B, Melo-Cardenas J, Zhang B, Zhang J, Song J, <u>Zhang DD</u>, Zhang J, Fan Y, Li H, Fang D. The ER membrane-anchored ubiquitin ligase Hrd1 is a positive regulator of T-cell immunity. *Nat Commun.* 2016. PMID:27417417
- 90: Sun J, Hoying JB, Deymier PA, <u>Zhang DD</u>, Wong PK. Cellular Architecture Regulates Collective Calcium Signaling and Cell Contractility. *PLoS Comput Biol.* 2016. PMID:27196735
- 89: Corenblum MJ, Ray S, Remley QW, Long M, Harder B, <u>Zhang DD</u>, Barnes CA, Madhavan L. Reduced Nrf2 expression mediates the decline in neural stem cell function during a critical middle-age period. *Aging Cell.* 2016. PMID:27095375
- Tang Q, Liang M, Lu Y, Wong PK, Wilmink GJ, <u>Zhang DD</u>, Xin H. Microfluidic Devices for Terahertz Spectroscopy of Live Cells Toward Lab-on-a-Chip Applications. *Sensors (Basel)*. 2016. PMID:27049392
- 87: Wang H, Liu X, Long M, Hunag Y, Zhang L, Zhang R, Zheng Y, Liao X, Wang Y, Liao Q, Li W,

Tang Z, Tong Q, Wang X, Fang F, Long M, Rojo de la Vega M, Ouyang Q, <u>Zhang DD\*</u>, Yu S\*, and Zheng H\*. NRF2 activation by anti-diabetic agents accelerates tumor metastasis. *Sci Transl Med*. 2016. PMID:27075625

- 86: Melo-Cardenas J, Zhang Y, <u>Zhang DD</u>, Fang D. Ubiquitin-specific peptidase 22 functions and its involvement in disease. **Oncotarget.** 2016. PMID:27057639
- 85: Wang Y, Wang Y, Zhang Z, Park JY, Guo D, Liao H, Yi X, Zheng Y, <u>Zhang DD</u>, Chambers SK, Zheng W. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway. **Oncotarget.** 2016. PMID:26824415
- 84: Chen W, Li S, Li J, Zhou W, Wu S, Xu S, Cui K, <u>Zhang DD</u>, Liu B. Artemisitene activates the Nrf2dependent antioxidant response and protects against bleomycin-induced lung injury. *FASEB J*. 2016. PMID:27006451
- 83: Tao S, Rojo de la Vega M, Quijada H, Wondrak GT, Wang T, Garcia JG, <u>Zhang DD</u>.\_Bixin protects mice against ventilation-induced lung injury in an NRF2-dependent manner.\_*Sci Rep.* 2016. PMID:26729554
- 82: Long M, Rojo de la Vega M, Wen Q, Bharara M, Jiang T, Zhang R, Zhou S, Wong PK, Wondrak GT, Zheng H, <u>Zhang DD</u>. An Essential Role of NRF2 in Diabetic Wound Healing. <u>*Diabetes.*</u> 2016. PMID:26718502
- 81: Yin YW, Jin HJ, Zhao W, Gao B, Fang J, Wei J, <u>Zhang DD</u>, Zhang J, Fang D. The Histone Acetyltransferase GCN5 Expression Is Elevated and Regulated by c-Myc and E2F1 Transcription Factors in Human Colon Cancer. *Gene Expr.* 2015. PMID:26637399
- 80: Qian Z, Zhou T, Gurguis CI, Xu X, Wen Q, Lv J, Fang F, Hecker L, Cress AE, Natarajan V, Jacobson JR, <u>Zhang DD</u>, Garcia JG, Wang T. Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival. *Sci Rep.* 2015. PMID:26596768
- 79: Tao S, Park SL, de la Vega MR, <u>Zhang DD</u>, Wondrak GT. Systemic administration of the pocarotenoid bixin protects skin against solar UV-induced damage through activation of NRF2. *Free Radic Biol Med*. 2015. PMID:26456052
- 78: Wang S, Riahi R, Li N, <u>Zhang DD</u>, Wong PK. Biosensors: Single Cell Nanobiosensors for Dynamic Gene Expression Profiling in Native Tissue Microenvironments (Adv. Mater. 39/2015). *Adv Mater*. 2015. PMID:26466935
- 77: Tao S, Tillotson J, Wijeratne EM, Xu YM, Kang M, Wu T, Lau EC, Mesa C, Mason DJ, Brown RV, La Clair JJ, Gunatilaka AA, <u>Zhang DD\*</u> and Chapman E\*. Withaferin A Analogs That Target the AAA+ Chaperone p97. **ACS Chem Biol**. 2015. PMID:26006219
- 76: Shen T, Jiang T, Long M, Chen J, Ren D, Wong PK, Chapman E, Zhou B and <u>Zhang DD</u>. A curcumin derivative that inhibits vinyl carbamate-induced lung carcinogenesis via activation of the Nrf2 protective response. *Antioxid Redox Signal*. 2015. PMID:25891177
- 75: Riahi R, Sun J, Wang S, Long M, <u>Zhang DD</u>, Wong PK. Notch1-Dll4 signalling and mechanical force regulate leader cell formation during collective cell migration. **Nat Commun**. 2015. PMID:25766473
- 74: Long M, Tao S, Rojo de la Vega M, Jiang T, Wen Q, Park SL, <u>Zhang DD</u>\*, Wondrak GT\*. Nrf2dependent suppression of azoxymethane/dextran sulfate sodium-induced colon carcinogenesis by the cinnamon-derived dietary factor cinnamaldehyde. *Cancer Prev Res*. 2015. PMID:25712056
- 73: Bao L, Jaramillo MC, Zhang Z, Zheng Y, Yao M, <u>Zhang DD</u>, Yi X. Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells. *Mol Med Rep*. 2015. PMID:25322694
- 72: Canet MJ, Merrell MD, Harder BG, Maher JM, Wu T, Lickteig AJ, Jackson JP, <u>Zhang DD</u>, Yamamoto M, Cherrington NJ. Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene. *Drug Metab Dispos*. 2015. PMID:25349122
- 71: Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, <u>Zhang DD</u>. Oncogenic KRAS confers chemoresistance by upregulating NRF2. *Cancer Res*. 2014. PMID:25339352.
- 70: Nam KH, Jamilpour N, Mfoumou E, Wang FY, <u>Zhang DD</u>, Wong PK. Probing mechanoregulation of neuronal differentiation by plasma lithography patterned elastomeric substrates. *Sci Rep*. 2014. PMID:25376886

- 69: Kang MJ, Wu T, Wijeratne EM, Lau EC, Mason DJ, Mesa C, Tillotson J, <u>Zhang DD</u>, Gunatilaka AA, La Clair JJ, Chapman E. Functional chromatography reveals three natural products that target the same protein with distinct mechanisms of action. *Chembiochem*. 2014. PMID:25125376
- 68: Wu T, Harder BG, Wong PK, Lang JE, <u>Zhang DD</u>. Oxidative stress, mammospheres and Nrf2new implication for breast cancer therapy? **Mol Carcinog**. 2014. PMID:25154499.
- 67: Riahi R, Wang S, Long M, Li N, Chiou PY, <u>Zhang DD</u>, Wong PK. Mapping photothermally induced gene expression in living cells and tissues by nanorod-locked nucleic acid complexes. **ACS Nano**. 2014. PMID:24645754
- 66: Wu T, Zhao F, Gao B, Tan C, Yagishita N, Nakajima T, Wong PK, Chapman E, Fang D, <u>Zhang</u> <u>DD</u>. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. **Genes Dev**. 2014. PMID:24636985
- 65: Shen T, Chen XM, Harder B, Long M, Wang XN, Lou HX, Wondrak GT, Ren DM, <u>Zhang DD</u>. Plant extracts of the family Lauraceae: a potential resource for chemopreventive agents that activate the nuclear factor-erythroid 2-related factor 2/antioxidant response element pathway. *Planta Med*. 2014. PMID:24585092
- 64: Riahi R, Long M, Yang Y, Dean Z, <u>Zhang DD</u>, Slepian MJ, Wong PK. Single cell gene expression analysis in injury-induced collective cell migration. *Integr Biol* (*Camb*). 2014. PMID:24336811
- 63: Wu T, Wang XJ, Tian W, Jaramillo MC, Lau A, <u>Zhang DD</u>. Poly(ADP-ribose) polymerase-1 modulates Nrf2-dependent transcription. *Free Radic Biol Med*. 2014. PMID:24140708
- 62: Jiang T, Tian F, Zheng H, Whitman SA, Lin Y, Zhang Z, Zhang N, <u>Zhang DD</u>. Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response. *Kidney Int.* 2014. PMID:24025640
- 61: Bao LJ, Jaramillo MC, Zhang ZB, Zheng YX, Yao M, <u>Zhang DD</u>, Yi XF. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. *Int J Clin Exp Pathol*. 2014. PMID:24817946
- 60: Qiao S, Tao S, Rojo de la Vega M, Park SL, Vonderfecht AA, Jacobs SL, <u>Zhang DD</u>, Wondrak GT. The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death. *Autophagy*. 2013. PMID:24113242
- 59: Tao S, Zheng Y, Lau A, Jaramillo MC, Chau BT, Lantz RC, Wong PK, Wondrak GT, <u>Zhang DD</u>. Tanshinone I activates the Nrf2-dependent antioxidant response and protects against As(III)induced lung inflammation in vitro and in vivo. *Antioxid Redox Signal*. 2013. PMID:23394605
- 58: Whitman SA, Long M, Wondrak GT, Zheng H, <u>Zhang DD</u>. Nrf2 modulates contractile and metabolic properties of skeletal muscle in streptozotocin-induced diabetic atrophy. *Exp Cell Res*. 2013. PMID:23896025
- 57: Qiu Q, Zheng Z, Chang L, Zhao YS, Tan C, Dandekar A, Zhang Z, Lin Z, Gui M, Li X, Zhang T, Kong Q, Li H, Chen S, Chen A, Kaufman RJ, Yang WL, Lin HK, <u>Zhang D</u>, Perlman H, Thorp E, Zhang K, Fang D. Toll-like receptor-mediated IRE1α activation as a therapeutic target for inflammatory arthritis. *EMBO J*. 2013. PMID:23942232
- 56: Riahi R, Dean Z, Wu TH, Teitell MA, Chiou PY, <u>Zhang DD</u>, Wong PK. Detection of mRNA in living cells by double-stranded locked nucleic acid probes. *Analyst*. 2013. PMID:23772441
- 55: Chen W, Wang H, Tao S, Zheng Y, Wu W, Lian F, Jaramillo M, Fang D, <u>Zhang DD</u>. Tumor protein translationally controlled 1 is a p53 target gene that promotes cell survival. **Cell Cycle**. 2013. PMID:24067374
- 54: Villeneuve NF, Tian W, Wu T, Sun Z, Lau A, Chapman E, Fang D, <u>Zhang DD</u>. USP15 negatively regulates Nrf2 through deubiquitination of Keap1. *Mol Cell*. 2013. PMID:23727018
- 53: Lau A, Zheng Y, Tao S, Wang H, Whitman SA, White E, <u>Zhang DD</u>. Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner. *Mol Cell Biol*. 2013. PMID:23589329
- 52: Lu Y, Gao J, <u>Zhang DD</u>, Gau V, Liao JC, Wong PK. Single cell antimicrobial susceptibility testing

by confined microchannels and electrokinetic loading. Anal Chem. 2013. PMID:234452

- 51: Wu W, Qiu Q, Wang H, Whitman SA, Fang D, Lian F, <u>Zhang DD</u>. Nrf2 is crucial to graft survival in a rodent model of heart transplantation. **Oxid Med Cell Longev**. 2013. PMID:23533698
- 50: Ji L, Li H, Gao P, Shang G, <u>Zhang DD</u>, Zhang N, Jiang T. Nrf2 pathway regulates multidrugresistance-associated protein 1 in small cell lung cancer. **PLoS One**. 2013. PMID:23667609
- 49: Tao S, Justiniano R, <u>Zhang DD</u>, Wondrak GT. The Nrf2-inducers tanshinone I and dihydrotanshinone protect human skin cells and reconstructed human skin against solar simulated UV. *Redox Biol*. 2013. PMID:24273736
- 48: Zheng Y, Tao S, Lian F, Chau BT, Chen J, Sun G, Fang D, Lantz RC, <u>Zhang DD</u>. Sulforaphane prevents pulmonary damage in response to inhaled arsenic by activating the Nrf2-defense response. *Toxicol Appl Pharmacol*. 2012. PMID:22975029
- 47: Chen W, Jiang T, Wang H, Tao S, Lau A, Fang D, <u>Zhang DD</u>. Does Nrf2 contribute to p53mediated control of cell survival and death? *Antioxid Redox Signal*. 2012. PMID:22559194
- 46: Wang F, Tian F, Whitman SA, <u>Zhang DD</u>, Nishinaka T, Zhang N, Jiang T. Regulation of transforming growth factor β1-dependent aldose reductase expression by the Nrf2 signal pathway in human mesangial cells. *Eur J Cell Biol*. 2012. PMID:22951256
- 45: Hu Q, <u>Zhang DD</u>, Wang L, Lou H, Ren D. Eriodictyol-7-O-glucoside, a novel Nrf2 activator, confers protection against cisplatin-induced toxicity. *Food Chem Toxicol*. 2012. PMID:22465804
- 44: Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B, Dong H, Wei J, Song J, <u>Zhang DD</u>, Fang D. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. **Mol Cell**. 2012. PMID:22542455
- 43: Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, Mehta M, Cheung KL, Ganesan S, Kong AN, <u>Zhang DD</u>, Xia B. PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. **Mol Cell Biol**. 2012. PMID:22331464
- 42: Riahi R, Yang Y, <u>Zhang DD</u>, Wong PK. Advances in wound-healing assays for probing collective cell migration. *J Lab Autom*. 2012. PMID:22357609
- 41: Bray K, Mathew R, Lau A, Kamphorst JJ, Fan J, Chen J, Chen HY, Ghavami A, Stein M, DiPaola RS, <u>Zhang D</u>, Rabinowitz JD, White E. Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. *PLoS One*. 2012. PMID:22848625
- 40: Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, <u>Zhang DD</u>. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. **Diabetes**. 2011. PMID:22025779
- 39: Kong S, Kim SJ, Sandal B, Lee SM, Gao B, <u>Zhang DD</u>, Fang D. The type III histone deacetylase Sirt1 protein suppresses p300-mediated histone H3 lysine 56 acetylation at Bclaf1 promoter to inhibit T cell activation. *J Biol Chem*. 2011. PMID:21454709
- 38: Sun Z, Wu T, Zhao F, Lau A, Birch CM, <u>Zhang DD</u>. KPNA6 (Importin {alpha}7)-mediated nuclear import of Keap1 represses the Nrf2-dependent antioxidant response. **Mol Cell Biol**. 2011. PMID:21383067
- 37: Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, <u>Zhang DD</u>. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. *Proc Natl Acad Sci U S A*. 2011. PMID:21205897
- 36: Chen N, Yi X, Abushahin N, Pang S, <u>Zhang D</u>, Kong B, Zheng W. Nrf2 expression in endometrial serous carcinomas and its precancers. *Int J Clin Exp Pathol*. 2010. PMID:21228930
- 35: Chen HC, Gau V, <u>Zhang DD</u>, Liao JC, Wang FY, Wong PK. Statistical metamodeling for revealing synergistic antimicrobial interactions. **PLoS One**. 2010. PMID:21124958
- 34: Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, Sun Z, White E, <u>Zhang DD</u>. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. *Mol Cell Biol*. 2010. PMID:20421418
- 33: Jiang T, Chen N, Zhao F, Wang XJ, Kong B, Zheng W, <u>Zhang DD</u>. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. *Cancer Res*. 2010. PMID:20530669
- 32: Hur W, Sun Z, Jiang T, Mason DE, Peters EC, <u>Zhang DD</u>, Luesch H, Schultz PG, Gray NS. A

small-molecule inducer of the antioxidant response element. *Chem Biol*. 2010. PMID:20534351

- 31: Wondrak GT, Villeneuve NF, Lamore SD, Bause AS, Jiang T, <u>Zhang DD</u>. The cinnamon-derived dietary factor cinnamic aldehyde activates the Nrf2-dependent antioxidant response in human epithelial colon cells. *Molecules*. 2010. PMID:20657484
- 30: Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, <u>Zhang DD</u>. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. *Diabetes*. 2010. PMID:20103708
- 29: Chen CH, Lu Y, Sin ML, Mach KE, <u>Zhang DD</u>, Gau V, Liao JC, Wong PK. Antimicrobial susceptibility testing using high surface-to-volume ratio microchannels. *Anal Chem*. 2010. PMID:20055494
- 28: Chen A, Gao B, Zhang J, McEwen T, Ye SQ, <u>Zhang D</u>, Fang D. The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-cell death by catalyzing EGR2 ubiquitination. *Mol Cell Biol*. 2009. PMID:19651900
- 27: Jiang T, Huang Z, Chan JY, <u>Zhang DD</u>. Nrf2 protects against As(III)-induced damage in mouse liver and bladder. **Toxicol Appl Pharmacol**. 2009. PMID:19538980
- 26: Zhao F, Wu T, Lau A, Jiang T, Huang Z, Wang XJ, Chen W, Wong PK, <u>Zhang DD</u>. Nrf2 promotes neuronal cell differentiation. *Free Radic Biol Med*. 2009. PMID:19573594
- 25: Sun Z, Huang Z, <u>Zhang DD</u>. Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response. **PLoS One**. 2009. PMID:19668370
- 24: Gidwani V, Riahi R, <u>Zhang DD</u>, Wong PK. Hybridization kinetics of double-stranded DNA probes for rapid molecular analysis. *Analyst*. 2009. PMID:20448937
- 23: Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, <u>Zhang DD</u>. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. *Mol Cell*. 2009. PMID: 19560419
- 22: Sun Z, Chin YE, <u>Zhang DD</u>. Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. **Mol Cell Biol.** 2009. PMID:19273602
- 21: Wang XJ, <u>Zhang DD</u>. Ectodermal-neural cortex 1 down-regulates Nrf2 at the translational level. *PLoS One*. 2009. PMID:19424503
- 20: Du Y, Villeneuve NF, Wang XJ, Sun Z, Chen W, Li J, Lou H, Wong PK, <u>Zhang DD</u>. Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. *Environ Health Perspect*. 2008. PMID:18795156
- Wondrak GT, Cabello CM, Villeneuve NF, Zhang S, Ley S, Li Y, Sun Z, <u>Zhang DD</u>. Cinnamoylbased Nrf2-activators targeting human skin cell photo-oxidative stress. *Free Radic Biol Med*. 2008. PMID:18482591
- 18: Wang Z, Gidwani V, <u>Zhang DD</u>, Wong PK. Separation-free detection of nuclear factor kappa B with double-stranded molecular probes. *Analyst*. 2008. PMID:18645638.
- 17: Meserve D, Wang Z, <u>Zhang DD</u>, Wong PK. A double-stranded molecular probe for homogeneous nucleic acid analysis. *Analyst*. 2008. PMID:18645642.
- 16: Wang XJ, Sun Z, Chen W, Li Y, Villeneuve NF, <u>Zhang DD</u>. Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction. *Toxicol Appl Pharmacol.* 2008. PMID:18417180
- 15: Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, <u>Zhang DD</u>. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. *Carcinogenesis*. 2008. PMID:18413364
- 14: Gao B, Lee SM, Chen A, Zhang J, <u>Zhang DD</u>, Kannan K, Ortmann RA, Fang D. Synoviolin promotes IRE1 ubiquitination and degradation in synovial fibroblasts from mice with collagen-induced arthritis. *EMBO Rep*. 2008. PMID:18369366
- Wang XJ, Sun Z, Chen W, Eblin KE, Gandolfi JA, <u>Zhang DD</u>. Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity. *Toxicol Appl Pharmacol*. 2007. PMID:17765279
- 12: Sun Z, Zhang S, Chan JY, Zhang DD. Keap1 controls postinduction repression of the Nrf2-

mediated antioxidant response by escorting nuclear export of Nrf2. *Mol Cell Biol*. 2007. PMID: 17636022

# (Beginning of the independent position at University of Arizona)

- 11: Ansell PJ, Lo SC, Newton LG, Espinosa-Nicholas C, <u>Zhang DD</u>, Liu JH, Hannink M, Lubahn DB. Repression of cancer protective genes by 17beta-estradiol: ligand-dependent interaction between human Nrf2 and estrogen receptor alpha. **Mol Cell Endocrinol**. 2005. PMID:16198475
- 10: <u>Zhang DD</u>, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. *J Biol Chem*. 2005. PMID:15983046
- 9: Li X, <u>Zhang D</u>, Hannink M, Beamer LJ. Crystal structure of the Kelch domain of human Keap1. **J Biol Chem**. 2004. PMID:15475350
- 8: <u>Zhang DD</u>, Lo SC, Cross JV, Templeton DJ, Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. *Mol Cell Biol*. 2004. PMID:15572695
- 7: Li X, <u>Zhang D</u>, Hannink M, Beamer LJ. Crystallization and initial crystallographic analysis of the Kelch domain from human Keap1. *Acta Crystallogr D Biol Crystallogr*. 2004. PMID:15583386
- 6: <u>Zhang DD</u>, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. **Mol Cell Biol**. 2003. PMID:14585973
- 5: Cullinan SB, <u>Zhang D</u>, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. *Mol Cell Biol*. 2003. PMID:14517290
- 4: Salnikow K, Davidson T, Kluz T, Chen H, <u>Zhou D</u><sup>#</sup>, Costa M. GeneChip analysis of signaling pathways effected by nickel. *J Environ Monit*. 2003. PMID:12729255
- 3: <u>Zhang DD</u>, Hartsky MA, Warheit DB. Time course of quartz and TiO(2) particle-induced pulmonary inflammation and neutrophil apoptotic responses in rats. *Exp Lung Res*. 2002. PMID: 12490038
- 2: Sachdev S, Bagchi S, <u>Zhang DD</u>, Mings AC, Hannink M. Nuclear import of IkappaBalpha is accomplished by a ran-independent transport pathway. **Mol Cell Biol**. 2000. PMID:10669735
- 1: <u>Zhou D</u><sup>#</sup>, Salnikow K, Costa M. Cap43, a novel gene specifically induced by Ni2+ compounds. **Cancer Res**. 1998. PMID:9605764 \*Co-corresponding author <sup>#</sup>Zhou D. is the former name of Zhang DD

# **Reviews, Perspectives and Commentaries:**

- 27: <u>Zhang DD</u>, Chapman E. The role of natural products in revealing NRF2 function. *Nat Prod Rep*. 2020. PMID:32400766
- 26: Anandhan A, Dodson M, Schmidlin CJ, Liu P, <u>Zhang DD</u>. Breakdown of an Ironclad Defense System: The Critical Role of NRF2 in Mediating Ferroptosis. *Cell Chem Biol.* 2020. PMID:32275864
- 25: Schmidlin CJ, Dodson MB, <u>Zhang DD</u>. Filtering through the role of NRF2 in kidney disease. **Arch** *Pharm Res.* 2019. PMID:31372933
- 24: Dodson M, Castro-Portuguez R, <u>Zhang DD</u>. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. *Redox Biol*. 2019. PMID:30692038.
- 23: Schmidlin CJ, Dodson MB, Madhavan L, <u>Zhang DD</u>. Redox regulation by NRF2 in aging and disease. *Free Radic Biol Med*. 2019. PMID:30654017.
- 22: Dodson M, de la Vega MR, Cholanians AB, Schmidlin CJ, Chapman E, <u>Zhang DD</u>. Modulating NRF2 in Disease: Timing Is Everything. *Annu Rev Pharmacol Toxicol*. 2018. PMID:30256716
- 21: Rojo de la Vega M, Chapman E, <u>Zhang DD</u>. NRF2 and the Hallmarks of Cancer. **Cancer Cell**. 2018. PMID:29731393
- 20: Rojo de la Vega M, <u>Zhang DD</u>. NRF2 Induction for NASH Treatment: A New Hope Rises. **Cell Mol Gastroenterol Hepatol**. 2018. PMID:29675456

- 19: Rojo de la Vega M, Krajisnik A, <u>Zhang DD</u>, Wondrak GT. Targeting NRF2 for Improved Skin Barrier Function and Photoprotection: Focus on the Achiote-Derived Apocarotenoid Bixin. *Nutrients.* 2017. Review. PMID:29258247
- 18: Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, <u>Zhang DD.</u> Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. **Cell.** 2017. PMID:28985560.
- 17: Dodson M, <u>Zhang DD</u>. Non-Canonical activation of NRF2: New insights and its relevance to disease. *Curr Pathobiol Rep.* 2017. PMID:29082113.
- 16 Long M, Li X, Li L, Dodson M, <u>Zhang DD</u>, Zheng H. Multifunctional p62 Effects Underlie Diverse Metabolic Diseases. *Trends Endocrinol Metab.* 2017. PMID:28966079.
- 15: de la Vega MR, Dodson M, Chapman E, <u>Zhang DD</u>. NRF2-targeted therapeutics: New targets and modes of NRF2 regulation. <u>*Curr Opin Toxicol*</u>. 2016. PMID:29082352.
- 14: Wang H, Rojo de la Vega M, <u>Zhang DD</u>\*, Yu S\*, Zheng H\*. Response to comment on "NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis". *Sci Transl Med.* 2016. PMID:27464746
- 13: de la Vega MR, Dodson M, Gross C, Manzour H, Lantz RC, Chapman E, Wang T, Black SM, Garcia JG, <u>Zhang DD</u>. Role of Nrf2 and Autophagy in Acute Lung Injury. *Curr Pharmacol Rep.* 2016. PMID:27313980
- 12: Klionsky DJ, Abdelmohsen K, Abe A, et. al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*. 2016. PMID:26799652
- 11: Jiang T, Harder B, Rojo de la Vega M, Wong PK, Chapman E, <u>Zhang DD</u>. P62 links autophagy and NRF2 signaling. *Free Radic Biol Med*. 2015. PMID:26117325
- 10: Harder B, Jiang T, Wu T, Tao S, Rojo de la Vega M, Chapman E, <u>Zhang DD</u>. Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention. **Biochem. Soc. Trans**. 2015. PMID:26551712
- 9: Jaramillo MC, <u>Zhang DD</u>. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. *Genes Dev*. 2013. PMID:24142871
- 8: <u>Zhang DD</u>. Bardoxolone brings Nrf2-based therapies to light. *Antioxid Redox Signal*. 2013. PMID:23227819
- 7: Lau A, Whitman SA, Jaramillo MC, <u>Zhang DD</u>. Arsenic-mediated activation of the Nrf2-Keap1 antioxidant pathway. *J Biochem Mol Toxicol*. 2013. PMID:23188707
- 6: Lau A, Tian W, Whitman SA, <u>Zhang DD</u>. The predicted molecular weight of Nrf2: it is what it is not. *Antioxid Redox Signal*. 2013. PMID:22703241
- 5: Villeneuve NF, Lau A, <u>Zhang DD</u>. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. *Antioxid Redox Signal*. 2010. PMID:20486766
- 4: <u>Zhang DD</u>. The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. *Antioxid Redox Signal*. 2010. PMID:20486759
- 3: Villeneuve NF, Sun Z, Chen W, <u>Zhang DD</u>. Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels. **Cell Cycle**. 2009. PMID:19806015
- 2: Lau A, Villeneuve NF, Sun Z, Wong PK, <u>Zhang DD</u>. Dual roles of Nrf2 in cancer. **Pharmacol Res**. 2008. PMID:18838122
- 1: <u>Zhang DD</u>. Mechanistic studies of the Nrf2-Keap1 signaling pathway. **Drug Metab Rev**. 2006. PMID:17145701

# Book chapters:

 Comprehensive Toxicology, 3<sup>rd</sup> Edition. Elsevier. Editor-in-Chiefs: Charlene McQueen. ISBN: 9780081006016 *Chapter:* Oxidative Signaling. de la Vega MR, Dodson M, <u>Zhang DD</u>. 2017 2: Johnson J, Puga A, Wallace KB, and <u>Zhang DD</u>. Editorial Overview: Nrf2 in Toxicology: An Update. <u>Curr Opin Toxicol</u>. 2016,1.

# Chapter:

de la Vega MR, Dodson M, Chapman E, <u>Zhang DD</u>. NRF2-targeted therapeutics: New targets and modes of NRF2 regulation. <u>*Curr Opin Toxicol*</u>. 2016 Dec;1:62-70.

1: <u>Zhang DD</u>. 2010. The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. *Antioxid Redox Signal*.

#### Chapter:

Villeneuve NF, Lau A, <u>Zhang DD</u>. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. *Antioxid Redox Signal*. 2010 Dec 1;13(11):1699-712.

# SCHOLARLY PRESENTATIONS: (In the current position)

### Invited symposiums:

- Sept. 2019 Twenty-Third Heidelberger Symposium on Cancer Research, Stintino, Sardinia, Italy. Talk: "The intricacies of NRF2 regulation in cancer"
- Sept. 2019 International Symposium, "Molecular mechanisms of the environmental response to food and oxygen V" Sendai, Japan. Talk: "The NRF2 signaling network: crosstalk with ferroptosis and hedgehog signaling pathways"
- July 2019 ICTXV, Society of Toxicology, Honolulu, Hawaii. Section: "Recent trends in research on arsenic toxicity" Talk: "Arsenic in oxidative stress vs. proteotoxic stress."
- June 2019 Symposium "Araucária Symposium of Cell Biology", Curitiba, Brizil Talk: "The NRF2-KEAP1-ARE signaling pathway: regulation and dual role in cancer."
- May 2019 University of Iowa, Carver College of Medicine. The Fourth Forum "Signaling pathways and non-coding RNAs in carcinogenesis, prevention and therapy of malignant tumors". Talk: "The NRF2-KEAP1-ARE signaling pathway in cancer prevention and treatment."
- Mar. 2019 The Society of Toxicology annual meeting, Baltimore, US. Section: "Role of oxidative stress in health and disease: mechanism, methods of detection, and biomarkers" Talk: "NRF2, oxidative stress, and inflammatory lung injury?"
- Nov. 2018 Cold Spring Harbor Conference Asia, Suzhou, China "NRF2, ROS, and Ferroptosis in human disease."
- Nov. 2018 The Gerontological Society of America (GSA) 2018 Annual Scientific Meeting Biological Sciences Presidential Symposium: Free Radicals and Redox Regulation in Aging "Reactive oxygen species and NRF2 signaling in human aging and diseases"
- April. 2018 ASPET Annual Meeting at EB-2018 "Canonical and Non-Canonical Pathways of NRF2 activation."
- March. 2018 Cancer Colloquium 2018, St Andrews "Nrf2, Primary Cilia and Hedgehog Signaling in Cancer."

Nov. 2017	GSK Sponsored NRF2 Symposium in Suburban Philadelphia "The Role of Nrf2 in disease prevention and intervention."
June 2017	4 <sup>th</sup> Red House Forum, International Obstetrics & Gynecology Summit. Shanghai, China. "The Dual Role of Nrf2 in Cancer."
April 2017	Better Cancer Therapy from Redox Biology. The Bunbury Center, Cold Spring Harbor Laboratory, NY. "Role of Nrf2 in Cancer initiation, progression and metastasis."
April 2017	Ferroptosis: A Critical Review. The Banbury Center, Cold Spring Harbor Laboratory, NY. "Nrf2: an integrator of cellular iron and redox signaling."
Oct. 2016	9 <sup>th</sup> conference on metal toxicity and carcinogenesis, Lexington, Kentucky, US. "Arsenic blocks autophagy by interfering with the autophagosome-lysosome fusion."
Oct. 2016	International Union of Toxicologists (IUTOX)/XIV International Congress of Toxicology, Merida, Maxico. Section: Molecular Toxicology Talk: "Arsenic blocks autophagy by interfering with the autophagosome-lysosome fusion"
Aug. 2016	Pioneer Century Science (PCS) Global Diabetes Conference. Theme: Innovation, Collaboration, Intergration, Globalization. Moscow, Russia. Talk: "The Role of Nrf2 in Diabetic Diseases"
Apr. 2016	American Society for Pharmacology and Experimental Therapeutics (ASPET), Federation of American Societies For Experimental Biology 2013 annual meeting, San Diego, CA. Section: "Advances in Toxicogenetics of Metals." Talk: "A Novel Mechanism of Arsenic in Modulating Autophagy and Nrf2 Stress Responses."
Mar. 2016	The Society of Toxicology annual meeting, New Orleans, Louisiana, US. Section: "Novel roles of reactive oxygen species (ROS) in human diseases: Why ROS never gets stale?" Talk; "Nrf2: Tumor suppressor or oncogene?"
Feb. 2016	6 <sup>th</sup> International Conference on Metals in Genetics, Chemical Biology and Therapeutics (ICMG-2016). Bangalore, India. Session VIA: Talk; "Nrf2 in arsenic toxicity and carcinogenicity"
Mar. 2015	The Society of Toxicology annual meeting, San Diego, CA. Section: "Nrf2 signaling pathways in model systems: a master regulator of neurotoxicity and a potential therapeutic target." Talk; "The molecular mechanisms of Nrf2 regulation beyond Keap1: developing therapeutics targeting the "correct" E3 ubiquitin ligase for Nrf2 activation"
Jan. 2015	International symposiums The Keap1/Nrf2 pathway in Health and Disease, Robinson College, Cambridge, UK "Nrf2: Molecular regulatory mechanisms and chemical modulation"
Nov. 2014	SFRBM Annual Meeting, Seattle, WA

	Plenary Session: The Keap1-Nrf2 signaling pathway: Role in disease and pharmacological approaches Talk "Nrf2 regulation and its dual role in cancer."
Oct. 2014	ROS in Biology and Cancer. The Banbury Center, Cold Spring Harbor Laboratory, NY Talk: "Nrf2 regulation and its dual role in cancer."
Feb. 2014	International Symposium, "Molecular mechanisms of the environmental response to food and oxygen IV" Sendai, Japan. Talk: "The molecular mechanisms of Nrf2 regulation beyond Keap1"
Nov. 2013	Boston U. Pharmacology & Experimental Therapeutics-Pfizer Symposium, Boston, MA Therapeutic Innovation: Oxidative Stress and The Next Generation of Discovery Talk: "The Nrf2-Keap1-ARE pathway and its dual roles in cancer."
Aug. 2013	Gordon Research Conferences on Cellular & Molecular Mechanisms of Toxicity, Andover, NH. Section: "Nuclear Factor (Erythroid-derived 2) – Like 2 (Nrf2): is it all Good?" Talk: "The regulation of Nrf2 and its dual role in cancer."
Jul. 2013	The 14 <sup>th</sup> SCBA International Symposium Section: "Autophagy in Development and Disease" Talk: "The role of autophagy in modulating the Nrf2-Keap1-ARE pathway"
Apr. 2013	The American Physiological Society, Federation of American Societies For Experimental Biology 2013 annual meeting, Boston, MA. Section: "Nrf2 Signal Pathway in Human Diseases as Novel Therapeutics." Talk: "The Nrf2-Keap1-ARE pathway and the dual roles of Nrf2 in cancer."
Oct. 2012	7 <sup>th</sup> conference on metal toxicity and carcinogenesis, Albuquerque, New Mexico, US. "The Distinct Mechanism of Nrf2 Activation by Arsenic."
Jul. 2012	The 1 <sup>st</sup> international Chinese Symposium on Free Radical, Lanzhou, China. "The Nrf2-Keap1-ARE pathway and the dual role of Nrf2 in cancer."
Jun. 2012	International Society for the Study of Xenobiotics (MDO-ISSX), Noordwijk aan Zee, Netherlands. "The Nrf2-Keap1-ARE pathway and the dual role of Nrf2 in cancer."
Oct. 2011	International Society for Trace Element Research in Humans (ISTERH), Antalya (Belek), Turkey. "Arsenic and the Nrf2-Keap1 pathway."
Jul. 2011	Outstanding New Environmental Health Scientist Forum, Research Triangle Park, North Carolina, US. "The protective role of Nrf2 against arsenic-induced toxicity and carcinogenicity."
Mar. 2011	50 <sup>th</sup> Anniversary of Society of Toxicology annual meeting, Washington, D. C., US. Chair: "New insights into the Nrf2-Keap1 pathway and its impact on human disease." Talk: "Getting caught in the web of Nrf2-Keap1."
Jul. 2010	Biological Reactive Intermediates International Conference VIII, Barcelona, Spain. Talk 1: "The role of the Keap1-Nrf2-Cul3 system in cancer chemoprevention by natural

products."

Talk 2: "The Nrf2-Keap1-ARE signaling pathway and its dual role in cancer."

- May. 2010 International Conference on Biomedical and Environmental Sciences and Technology, Beijing, China. "Regulation of the Nrf2-mediated antioxidant response by Keap1: The protective role of Nrf2 against arsenic induced toxicity and carcinogenicity"
- Nov. 2009 International Symposium, "Inflammation and Redox signaling," Seoul, Korea. "The role of Nrf2 in cancer: the dark side"
- Aug. 2009 Federation of American Societies for Experimental Biology annual meeting, "Histone deacetylases and reversible acetylation in signaling and disease," Lucca, Italy. "Regulation of the Nrf2-dependent antioxidant response."
- Feb. 2009 International Symposium, "Molecular mechanisms of the environmental response to food and oxygen III," Sendai, Japan.
   "Direct interaction between Nrf2 and p21<sup>Cip1/WAF1</sup> upregulates the Nrf2-mediated antioxidant response & acetylation in modulating the Nrf2 dependent antioxidant response."
- Nov. 2008 American College of Toxicology annual meeting, Tucson, Arizona, US. "The Nrf2-dependent cellular defense mechanism in arsenic toxicity."
- Jan. 2008 International Conference on Nano/Micro Engineered and Molecular Systems annual meeting, Sanya, China. "High-throughput screening of chemopreventive compounds that activates the Nrf2-dependent signaling transduction pathway."
- Jan. 2006 Biological Reactive Intermediates International Conference VII, Tucson, Arizona, US. "The Nrf2/Keap1 signaling pathway, oxidative stress, and chemoprevention."

#### Invited seminars:

Nov. 2019	John H. Blaffer lecture Series at MD Anderson "The role of NRF2 in cancer prevention and intervention"
May. 2019	Cancer Prevention and Control (CPC), UA cancer Center "NRF2, oxidative stress, and inflammatory lung injury"
Nov. 2018	Biology and Medical Sciences, Suzhou University, Suzhou, China "The NRF2-KEAP1-ARE Signal Pathway: Regulation and Dual Role in Cancer"
Oct. 2018	The University of Arkansas for Medical Sciences (UAMS) Cancer Institute Forum, Little Rock, AR "The intriguing role of NRF2 in cancer"
July 2018	GSK Partnerships, College of Pharmacy, University of Arizona "The dual role of NRF2 in cancer: development of NRF2 inhibitors"
Feb. 2018	BCP Journal Club Seminar, Department of Chemistry & Biochemistry, University of Arizona "Targeting Nrf2 for disease prevention and intervention"
Jan. 2018	Department of Chemistry & Chemical Biology, University of New Mexico "Targeting Nrf2 for disease prevention and intervention"

Dec. 2017	UAHS Pathobiology Lung Seminar "Targeting Nrf2 for disease prevention and intervention"
Nov. 2017	Department of Cell Biology, Albert Einstein College of Medicine "The role of Nrf2 in cancer prevention and intervention"
Oct. 2017	Basic Medical Sciences, College of Medicine, UA Phoenix. "The role of Nrf2 in cancer prevention and intervention."
Sept. 2017	Integrative Biosciences & Department of Pharmaceutical Sciences, Wayne State University. "Nrf2 in Environmental Response and Disease Intervention."
May 2017	Department of Cell Systems & Anatomy, UT Health. "Nrf2 in Environmental Response and Disease Intervention."
April 2017	Department of Toxicology & Cancer Biology, University of Kentucky. "Nrf2 in Environmental Response and Disease Intervention."
Feb. 2017	Cancer Center, Medical College of Wisconsin. "Nrf2 in Environmental Response and Disease Intervention."
June 2016	ICIMED Investigación en Ciencias Médicas, Universidad de Ciencias Médicas, Costa Rica. "The dual role of Nrf2 in cancer: chemical modulation of Nrf2 for cancer intervention."
March 2016	Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut "Nrf2 in Environmental Response and Disease Intervention."
Jan. 2016	Pharmacy and Pharmaceutical Sciences, University of Colorado "Nrf2 in Environmental Response and Disease Intervention."
Jan. 2016	Cancer Biology, the University of Arizona Cancer Center "Nrf2 in Environmental Response and Disease Intervention."
Jan. 2016	Cancer Prevention and Control Program, the University of Arizona Cancer Center "Nrf2 in Environmental Response and Disease Intervention."
Dec. 2015	The University of Arizona Cancer Center "Harnessing Nrf2 for Cytoprotection: From the Inside to the Outside."
Nov. 2015	Department of Pharmacology & Chemical Biology, University of Pittsburgh "The dual role of Nrf2 in cancer."
Nov. 2014	University of Nebraska-Lincoln, the Biochemistry Department, Redox Biology Center "The dual role of Nrf2 in cancer: Nrf2 modulators as a novel anti-cancer therapeutics."
Sep. 2014	University of Arizona Cancer Center, Cancer Biology Seminar "The dual role of Nrf2 in cancer: Modulators of the Nrf2-Keap1-ARE pathway as a novel anti-cancer therapeutics."
Aug. 2014	Ventana medical systems, Inc. Tucson, Arizona

	"The dual role of Nrf2 in cancer: Modulators of the Nrf2-Keap1-ARE pathway as a novel anti-cancer therapeutics."	
Jul. 2014	Natural Products Affinity Group (NPAG), San Diego, CA "Modulators of the Nrf2-Keap1-ARE pathway as novel therapeutics."	
Apr. 2014	Xinqiao Hospital Medical School, Third Military Medical University, Chongqing, China. "Modulators of the Nrf2-Keap1-ARE pathway as novel therapeutics."	
Apr. 2014	College of Pharmacy, Zhejiang Ocean University, Zhoushan, Zhejiang, China "Modulators of the Nrf2-Keap1-ARE pathway as novel therapeutics."	
Mar. 2014	The University of Southern California, Free Radical Institute, Los Angeles, CA. "The regulation of Nrf2 and its dual role in cancer."	
Nov. 2013	Sanofi, Tucson Research Center, Oro valley, AZ "Modulators of the Nrf2-Keap1-ARE pathway as novel therapeutics."	
Nov. 2013	Pfizer, Boston, MA "Modulators of the Nrf2-Keap1-ARE pathway as novel therapeutics."	
Jul. 2013	School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China. "The Nrf2-Keap1 pathway and its dual role in cancer."	
May. 2013	Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. "The Nrf2-Keap1 pathway and its dual role in cancer."	
Apr. 2013	Department of Pharmacology and Toxicology, School of Pharmacy, University of Missouri- Kansas City, Kansas, MO. "The Nrf2-Keap1-ARE pathway and its dual role in cancer."	
Feb. 2013	Van Andel Research Institute, Grand Rapids, MI. "The Nrf2-Keap1-ARE pathway and the dual role of Nrf2 in cancer."	
Aug. 2012	Department of Gynecology, Hospital of OB/GYN, Fudan University, Shanghai, China "The dual role of Nrf2 in cancer."	
Mar. 2012	Cancer Prevention and Control, University of Arizona cancer Center, Tucson, Arizona, US. "The Nrf2-Keap1-ARE pathway and the dual role of Nrf2 in cancer."	
Feb. 2012	Department of Pulmonary Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, US. "The Nrf2-Keap1-ARE pathway and the dual role of Nrf2 in cancer."	
Feb. 2012	Department of Pathology & Laboratory Medicine, Brown University, Providence, RI, US. "The Nrf2-Keap1-ARE pathway and a novel mechanism of Nrf2 induction by arsenic."	
Feb. 2012	College of Medicine-Phoenix, University of Arizona, Phoenix, Arizona, US. "The Nrf2-Keap1-ARE pathway and the dual role of Nrf2 in cancer."	
Jan. 2012	Cellular and Molecular Basis of Disease (CMBD) series, School of Medicine, The University of New Mexico, Albuquerque, New Mexico, US.	

"The Nrf2-Keap1-ARE pathway and it dual role in cancer."

Jan. 2012	NYU Langone Medical Center/Cancer Institute, New York University, New York. US. "The Nrf2-Keap1-ARE pathway and the dual role of Nrf2 in cancer."
Jan. 2012	Nelson Institute of Environmental Medicine, New York University, New York. US. "The protective role of Nrf2 in arsenic-induced toxicity and carcinogenicity."
Dec. 2011	King Abdullah University of Science and Technology, Jeddah, Saudi Arabia. "Cellular stress response and human disease."
Nov. 2011	Barshop Institute for Longevity and Aging Studies, San Antonio, Texas, US. "Dual role of Nrf2 in human disease."
Sep. 2011	Department of Chemical and Environmental Engineering, University of Arizona, Tucson, Arizona, US. "Cell-based high throughput screening of environmental pollutants."
Feb. 2011	Public Health, Chinese Medical University, Shenyang, China. "The Nrf2-mediated defense system."
Jan. 2011	Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, US. "The Nrf2-Keap1-ARE signaling pathway and its dual role in cancer."
May. 2010	Xinqiao Hospital Medical School, Third Military Medical University, Chongqing, China. "The Nrf2-Keap1-ARE signaling pathway and human diseases."
Mar. 2010	Department of Pharmacology, School of Medicine, Tucson, Arizona, US. "Molecular program of cellular defense."
Jan. 2010	Cancer Prevention and Control, Arizona Cancer Center, Tucson, Arizona, US. "Dual Role of Nrf2 in Cancer: The Nrf2-Keap1-ARE signaling pathway."
Dec. 2009	University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, US. "Dual role of Nrf2 in cancer: The Nrf2-Keap1-ARE signaling pathway."
Nov. 2009	College of Pharmacy, Seoul National University, Seoul, Korea. "Regulation of Nrf2-mediated antioxidant response."
Oct. 2009	The Cancer Institute of New Jersey (UMDNJ/CINJ), New Brunswick, New Jersey, US. "Dual role of Nrf2 in cancer: The Nrf2-Keap1-ARE signaling pathway."
Sep. 2009	Department of Pharmacology and Toxicology, College of Pharmacy, Tucson, Arizona, US. "The Regulation of an Antioxidant Response Mediated by The Nrf2-Keap1-ARE signaling pathway."
Apr. 2009	Nelson Institute of Environmental Medicine, New York University Medical School, New York, New York, US. "The Nrf2-dependent antioxidant response: the antioxidant function of p21 <sup>Cip1/WAF1</sup> is mediated by Nrf2."
Nov. 2008	Biological Chemistry Graduate Program, Tucson, Arizona, US.

	"Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during antioxidant response."
Jan. 2008	School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China. "The Nrf2-mediated endogenous antioxidant response."
Jan. 2008	Fudan Medical School, Fudan University, China . "The Nrf2-Keap1 signaling pathway and the endogenous antioxidant response."
Oct. 2007	National Institute of Environmental Health Science center director annual meeting, Corvallis, Oregon, US. "The protective role of Nrf2 in arsenic-induced toxicity and carcinogenicity."
Mar. 2007	Department of Pathology, University of California, Irvine, California, US. "The Nrf2-Keap1 signaling pathway and the endogenous antioxidant response."
Feb. 2007	Biodesign Institute, Arizona State University, Tempe, Arizona, US. "The Nrf2-Keap1 signaling pathway and the endogenous antioxidant response"
Nov. 2006	Biological Chemistry Graduate Program, Tucson, Arizona, US. "The Nrf2 signaling pathway."
Oct. 2006	National Institute of Environmental Health Science "The protective role of Nrf2 in arsenic-induced toxicity and carcinogenicity."
Sep. 2006	Cancer Biology Graduate Program, Arizona Cancer Center, Tucson, Arizone, US. "The Nrf2/Keap1 signaling pathway."
Sep. 2006	Superfund Colloquium, Tucson, Arizona, US "The protective role of Nrf2 in arsenic-induced toxicity and carcinogenicity."

#### **PROFESSIONAL SOCIETIES**

1996-present Society of Toxicology

#### **GRANT SUPPORT**

#### CURRENT

R35ES031575 (Zhang) NIH/NIEHS The major goals of this pl 06/01/2020-02/29/2028 \$606,023 direct/year 6.00 Person Months

The major goals of this project include in-depth mechanistic investigations of arsenic pathogenesis/NRF signaling and the translation of basic mechanistic knowledge into preclinical drug development. Role: PI

P42ES004940 (Maier)	04/01/2020-01/31/2025	2.35 Person Months
NIH/NIEHS	\$1,536,643	

Exposures, Health Impacts, and Risk for Mine Waste Contamination

The goal is to build a mechanistic model of the contributions of chronic mine waste-arsenic exposure to the development of diabetes and associated metabolic disease to inform risk assessment tools that can be used to predict exposures and associated health outcomes and to inform public health prevention and interventions in communities that neighbor mine waste sites.

Role: Associate Director/PI (Project 1)

R01DK109555 (Zhang)

07/15/2016-06/30/2021 2.40 Person Months

 Arsenic, Nrf2 and Autophagy Dysfunction in Type II Diabetes

 The goal for this project is to investigate the molecular mechanisms by which arsenic alters the proteotoxic and oxidative stress responses to determine if these alterations aid to the onset and progression of diabetes using cell lines and a high fat diet-induced type II diabetes mouse model.

 Role: Pl
 12/24/2018-11/30/2023
 0.60 Person Months \$197,976

 Selective Killing of FH-/- Cancer Cells by Targeting Cellular Iron Homeostasis
 This project investigates the feasibility and mechanisms of action of a novel rational drug combination

that can specifically target FH-/- cancer cells while sparing normal cells. This drug combination enhances FH-/- cancer cells' sensitivity to a cell death mechanism that is dependent on redox active iron. Role: Collaborator

P01HL126609 (Garcia) NIH/NHLBI 06/01/2016-03/31/2021 \$1,657,039 0.60 Person Months

Cytoskeletal Regulation of Lung Endothelial Pathobiology

In its 16th-20th year of proposed funding, the PPG will investigate the complex field of inflammatory lung injury, particularly, the spatial regulation of the dynamic actomyosin cytoskeleton (central stress fibers, lamellipodia formation, focal adhesion formation) involving MLCK, cortactin, c-Abl, EVL, and  $\beta$ -integrins. Role: Co-I

# OVERLAP

There is no scientific, budgetary, or commitment overlap.

# PENDING

HHMI Investigator Program (Zhang)

NRF-mediated Cellular Responses: mechanisms to therapy

The major goals of this program are to gain a deeper molecular understanding of NRF biology, such as how NRF1, 2, and 3 integrate with other cellular signaling pathways to maintain cellular homeostasis, and how dysregulation of NRF-mediated downstream events lead to human diseases. The research proposed in this application—from mechanistic insights of NRF, into the pathogenesis of NRF dysregulation, to NRF-based therapeutic intervention—will greatly "advance basic biomedical research and science education for the benefit of humanity", a mission of the Howard Hughes Medical Institute. Role: PI

# SUBMITTED

R01 (DMP study section) (Chapman/Zhang) NIH/NCI

**04/01/2021-01/31/2026** \$400,000 2.4 Person Months

Targeting NRF2 for Cancer Prevention

Lung cancer is the leading cause of cancer related deaths and is often driven by aberrant NRF2 expression - "NRF2 addiction". NRF2 is usually a protective transcription factor, but recently it has been shown to be dysregulated in a number of cancers, especially lung cancer. We aim to develop our lead molecule that targets NRF2 directly to combat lung cancer progression, metastasis, and chemoresistance. Role: MPI

R01 (XNDA study section) (Chapman) NIH/NIEHS 04/01/2021-01/31/2026 0.6 Person Months \$400,000

# Autophagy, NRF2, and PTP1B Connect Arsenic to Type 2 Diabetes

Epidemiological studies have shown a strong correlation between environmental exposure to arsenic and the development of type 2 diabetes, but a true molecular understanding of this process is lacking, preventing the development of a viable treatment strategy. We plan to test a highly innovative mechanistic

# NIH/NIDDK

# \$230,213

hypothesis that reveals a potential treatment strategy. We will simultaneously explore this strategy of treatment as a proof of concept and to further validate our model. Role: Co-I

#### COMPLETED

P42 ES004940 Maier (PD)/Zhang (PI) 04/01/2018-03/31/2019 Project 5: Role of Nrf2 in the Pulmonary Response to Inhaled Mine Tailing Dust This project investigates the mechanism by which arsenic-induced lung inflammation and dysfunction occur, which will enable the development of disease-preventive treatments for the populations at risk of arsenic.

R01 ES026845 Zhang (PI) NRF2, autophagy, and arsenic carcinogenesis

The goal of this project is to investigate the detailed mechanism by which arsenic causes lung cancer. In turn, this will allow us to pinpoint markers of exposure to identify populations at risk of developing arsenic-induced lung cancer as well as to develop tailored therapies for the individuals who have already developed arsenic-induced lung cancer.

R01 ES023758 Chapman/Zhang (MPI) 02/01/2014-10/31/2018 Stress Response, p97, and NRF2 in Arsenic-Mediated Toxicity This project investigated the biochemical mechanism of arsenic-mediated deregulation of p97, and NRF2, and dissected the interplay between arsenic, p97, autophagy, and NRF2.

#### R21 CA166926 Zhang/Wondrak (MPI)

Targeting colorectal carcinogenesis using a cinnamon-derived food factor This project is to test the overall hypothesis that the cinnamon-derived food factor cinnamaldehyde

represents a potent chemopreventive dietary factor targeting colorectal carcinogenesis through modulation of Nrf2-orchestrated cytoprotective mechanisms.

R01 CA154377 Zhang (PI)

Investigation of an anti-cancer phytochemical targeting NRF2

This project characterized the anti-cancer properties of brusatol, an inhibitor of the NRF2 pathway, using a preclinical lung cancer model and delineated the molecular targets and mechanistic actions of brusatol.

RSG-07-154-01-CNE Zhang (PI) American Cancer Society 07/01/2007-06/30/2012 Regulation of the Transcription Factor Nrf2 by Chemopreventive Compounds The major goals of this project are to define the mechanism of Nrf2 regulation in response to the treatment of chemopreventive compounds

R01 ES015010 (ONES) Zhang (PI)

The protective role of NRF2 in arsenic-induced toxicity and carcinogenicity This project aimed to define the protection of the transcription factor NRF2 against arsenic-induced toxicity and carcinogenicity and the mechanism of arsenic-mediated carcinogenicity.

01/01/2013-12/31/2014

08/15/2011-05/31/2017

09/01/2006-01/31/2017

07/01/2016-06/30/2020